Wolfgang Miesbach on Linus Völker’s Presentation of Caplacizumab as Frontline Therapy for iTTP
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”Caplacizumab as Frontline Therapy for iTTP: Is Plasmapheresis Still Needed? Priv.-Doz. Dr.med. Linus Völker presented at ASH compelling evidence that caplacizumab can work without plasma exchange in selected patients.
Systematic evidence: >100 plasma-free iTTP episodes
· First case reports and small series: ~10 episodes
· Kühne et al., Blood 2024 (Austria/Germany): 42 episodes with 90.5% clinical response without TPE and a median time to platelet normalization: 3 days (vs. 4 days with TPE, p=0.31), however, 4 patients required rescue TPE
· Knöbl, ISTH 2025: 34 episodes
· MAYARI Trial, ISTH 2025: 46 episodes and 93.5% remission without TPE (43/46 patients), 95.7% remission overall (44/46 patients)
This strategy is off-label and requires institutional capabilities:
✓ Extensive iTTP treatment experience at specialized centers
✓ 24/7 ADAMTS13 activity measurement (turnaround in hours, not days)
✓ Immediate caplacizumab access via emergency pharmacy
✓ Plasma exchange instantly available (safety net, not routine)
✓ No contraindications to caplacizumab therapy
Crucial to identify the right patient
There are clinical characteristics favoring a plasma-free approach
· Immediate platelet recovery after the first caplacizumab dose
· Clinically stable condition at presentation
· Lower LDH levels at onset
· Less severe organ involvement (lower ICU admission rates)
A fascinating glimpse into how frontline caplacizumab, in the right setting with the right patient, may allow truly plasma-free management for selected iTTP cases.”
All from ASH25 featured in Hemostasis Today.
-
Dec 17, 2025, 06:11Lisa Murphy Thanks Stroke Foundation Team for An Impactful, Rewarding and Incredible Year
-
Dec 17, 2025, 06:05Emmanuel J Favaloro Shares A Study on AI and Machine Learning in Thrombosis and Hemostasis
-
Dec 17, 2025, 05:54Michael Bruckman: Fantastic to See Platelet-Inspired Nanoparticles Gaining Attention!
-
Dec 17, 2025, 04:00Peter Verhamme on Genetic Predisposition to Thromboembolism and COVID
-
Dec 16, 2025, 23:14Shrinidhi Nathany: MRD in AML – From a Test to a Treatment Decision
-
Dec 16, 2025, 22:16Wolfgang Miesbach – Targeting VEGF to Stop GI Bleeding: Systemic Bevacizumab
-
Dec 16, 2025, 17:14Piotr Czempik Honored for His Work on Cost Reduction in Blood Transfusions
-
Dec 16, 2025, 17:06Davood KHoda Amorzideh on VTE and Bleeding in Cancer
-
Dec 16, 2025, 16:56Kathryn Mikkelsen on The Beat: Vasculearn Network’s Newsletter for Clot Survivors